Insmed's Phase III Drug Candidate to Be Featured in Two Podium Presentations at European Society for Paediatric Endocrinology.Business Editors/Health/Medical Writers BIOWIRE2K RICHMOND, Va.--(BUSINESS WIRE)--Sept. 15, 2003 Insmed Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :INSM) today announced that its Phase III drug candidate, rhIGF-I/rhIGFBP-3, will be featured in two podium presentation at the 42nd Annual Meeting of the European Society for Paediatric Endocrinolgy in Ljubljana, Slovenia, September 18-21. Ceclia Camacho-Hubner, M.D., of St. Bartholemew's Hospital, London, United Kingdom, will give the oral presentation entitled, "Recombinant Human Insulin-Like Growth Factor insulin-like growth factor one of the twenty or so substances, additional to the classic bone-regulating hormones, which exert an effect on bone cell metabolism. See also somatomedin C. (IGF (Internet Governance Forum) An international organization of governments and U.N. agencies that was founded to discuss Internet issues such as security and spam. It was created at the United Nations Summit in 2005 after the U.S. )-I/IGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome growth hormone insensitivity syndrome Laron dwarfism, pituitary dwarfism II An AR condition characterized by severe growth retardation, delayed bone age, occasionally blue sclerae, and physical manifestations of GH deficiency, due to a defect in the GH receptor ." This data was presented to The Endocrine Society's Annual Meeting, ENDO 2003. Tero Saukkonen, M.D., Division of Endocrinology and Diabetes, Hospital for Children and Adolescents, University of Helsinki The University of Helsinki is not to be confused with the Helsinki University of Technology. The University of Helsinki (Finnish: Helsingin yliopisto, Swedish: Helsingfors universitet , will give a second podium presentation entitled, "Effects of Combined Recombinant Human Insulin-Like Growth Factor I / Insulin-Like Growth Factor Binding Protein The Insulin-like growth factor binding protein serves as a carrier protein for Insulin-like growth factor 1. Approximately 98% of IGF-1 is always bound to one of 6 binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. 3 on Growth Hormone Secretion & Insulin Sensitivity in Adolescents with Type I Diabetes Type I diabetes Also called juvenile diabetes. Type I diabetes typically begins early in life. Affected individuals have a primary insulin deficiency and must take insulin injections. Mentioned in: Diabetic Ketoacidosis ." This data is an extension of a study that was previously presented at the 63rd Scientific Sessions of the ADA. Rachel Williams, M.D., Clinical Research Fellow, Department of Paediatrics, University of Cambridge will present a third abstract entitled, "The Effects of Administration of IGF-I/IGFBP-3 Complex (SomatoKine) on Levels of IGF-I IGF-I see somatomedin C. IGF-I Insulin-like growth factor I, somatomedin-C A polypeptide hormone structurally similar to proinsulin, synthesized in the liver and fibroblasts, giving fibroblasts a paracrine function; serum levels correlate with and IGFBP-3 and on IGFBP-3 Proteolysis proteolysis Process in which a protein is broken down partially, into peptides, or completely, into amino acids, by proteolytic enzymes, present in bacteria and in plants but most abundant in animals. in Type 1 Diabetes type 1 diabetes n. See diabetes mellitus. ." 42nd European Society for Paediatric Endocrinology Abstracts: -- Abstract OR5-48: "Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome" Session: GH/IGF-I, Friday, September 19, 9:45am -- Abstract OR4-45: "Effects of Combined Recombinant Human Insulin-Like Growth Factor I / Insulin-Like Growth Factor Binding Protein 3 on Growth Hormone Secretion & Insulin Sensitivity in Adolescents with Type I Diabetes" Session: Glucose Metabolism, Friday, September 19, 9:45am -- Abstract P2-243: "The Effects of Administration of IGF-I/IGFBP-3 Complex (SomatoKine) on Levels of IGF-I and IGFBP-3 and on IGFBP-3 Proteolysis in Type 1 Diabetes" Session: IGF's, IGFBP's and Growth Factors, Saturday, September 20. These abstracts will be available on Insmed's corporate website, www.insmed.com, on Friday, September 19. More on rhIGF-I/rhIGFBP-3 Insmed's rhIGF-I/rhIGFBP-3 is a proprietary delivery composition of insulin-like growth factor-I (IGF-I). The novel compound is administered as a once-daily subcutaneous injection, which can restore IGF levels to physiological relevant levels. In diabetic subjects, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in blood sugar control and a significant reduction in daily insulin use. Following severe burn injury, in both children and adults, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in muscle protein synthesis and a significant reduction in the inflammatory response associated with the trauma. In recovery from hip fractures, administration of rhIGF-I/rhIGFBP-3 has demonstrated a significant improvement in functional recovery and bone mineral density bone mineral density n. See bone density. bone mineral density A measurement of bone mass, expressed as the amount of mineral–in grams divided by the area scanned in cm2. See Bone densitometry. . rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the treatment of Growth Hormone Insensitivity Syndrome (GHIS). About Insmed Incorporated Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders. For more information, please visit www.insmed.com. Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion